Levetiracetam (All indications)

Low Apgar score (< 7) (at 1 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9029
R30781		 Bank (Levetiracetam) (Mixed indications), 2017 Apgar < 7 at 1 minute during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 2.83 [0.22;36.38] C 1/7   2/36 3 7
ref
S8983
R30477		 Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.46 [0.17;12.64] C
excluded (control group) 		1/12   9/154 10 12
ref
S8984
R30489		 Artama (Levetiracetam) (Controls unexposed, disease free), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.69 [0.22;13.21]
excluded (control group) 		1/12   27,939/689,482 27,940 12
ref
S8985
R30501		 Artama (Levetiracetam) (Controls unexposed, sick), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective unexposed, sick Adjustment: Yes 1.59 [0.19;13.08] 1/12   69/1,708 70 12
ref
Total 2 studies 2.01 [0.39;10.26] 73 19
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bank (Levetiracetam) (Mixed indications), 2017Bank, 2017 1 2.83[0.22; 36.38]3741%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Levetiracetam) (Controls unexposed, sick), 2013Artama, 2013 2 1.59[0.19; 13.08]701259%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.01[0.39; 10.26]73190.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Mixed indications; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.01[0.39; 10.26]73190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.59[0.19; 13.19]7012 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 exposed to other treatment, sickexposed to other treatment, sick 2.83[0.22; 36.38]37 -NABank (Levetiracetam) (Mixed indications), 2017 1 Tags Adjustment   - No  - No 2.83[0.22; 36.38]37 -NABank (Levetiracetam) (Mixed indications), 2017 1   - Yes  - Yes 1.59[0.19; 13.19]7012 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 All studiesAll studies 2.01[0.39; 10.26]73190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls unexposed, sick), 2013 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8983, 8984

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.69[0.22; 13.10]27,94012 -NAArtama (Levetiracetam) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 1.59[0.19; 13.19]7012 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.93[0.37; 10.00]13190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 20.510.01.0